Drug Information

Drug (ID: DG01897) and It's Reported Resistant Information

• Name: Trastuzumab-based chemotherapy
• Synonyms: Trastuzumab-based chemotherapy
• Target: .; NOUNIPROTAC; [1]

Type(s) of Resistant Mechanism of This Drug

  ADTT: Aberration of the Drug's Therapeutic Target

Drug Resistance Data Categorized by Their Corresponding Diseases

ICD-02: Benign/in-situ/malignant neoplasm

Lung cancer [ICD-11: 2C25]

Drug Sensitivity Data Categorized by Their Corresponding Mechanisms

Aberration of the Drug's Therapeutic Target (ADTT)

Key Molecule: Receptor tyrosine-protein kinase erbB-2 (ERBB2) [1]

• Molecule Alteration: Missense mutation; p.G776L (c.2326_2327delGGinsCT)
• Sensitive Disease: Lung adenocarcinoma [ICD-11: 2C25.0]
• Experimental Note: Identified from the Human Clinical Data
• In Vitro Model: Lung; N.A.
• Mechanism Description: The missense mutation p.G776L (c.2326_2327delGGinsCT) in gene ERBB2 cause the sensitivity of Trastuzumab-based chemotherapy by aberration of the drug's therapeutic target

Head and neck cancer [ICD-11: 2D42]

Drug Sensitivity Data Categorized by Their Corresponding Mechanisms

Aberration of the Drug's Therapeutic Target (ADTT)

Key Molecule: Receptor tyrosine-protein kinase erbB-2 (ERBB2) [2]

• Molecule Alteration: Copy number gain; .
• Sensitive Disease: Head and neck cancer [ICD-11: 2D42.0]
• Experimental Note: Identified from the Human Clinical Data
• In Vitro Model: Human salivary ductal carcinoma tissue; N.A.
• Mechanism Description: The copy number gain in gene ERBB2 cause the sensitivity of Trastuzumab-based chemotherapy by aberration of the drug's therapeutic target.

References

• Ref 1: HER2 mutation and response to trastuzumab therapy in non-small-cell lung cancerN Engl J Med. 2006 Jun 15;354(24):2619-21. doi: 10.1056/NEJMc060020.
• Ref 2: Targeted therapy with trastuzumab for advanced salivary ductal carcinoma: case report and literature reviewMed Oncol. 2012 Jun;29(2):704-6. doi: 10.1007/s12032-011-9884-1. Epub 2011 Mar 6.